HUTCHMED Company Top Insiders
| HMDCF Stock | USD 3.02 0.17 5.33% |
HUTCHMED employs about 2.1 K people. The company is managed by 10 executives with a total tenure of roughly 4924 years, averaging almost 492.0 years of service per executive, having 211.0 employees per reported executive. Examination of HUTCHMED's management performance can provide insight into the company performance.
| Selina Zhang Insider VP HR |
| Kin MBA Insider Sr Devel |
HUTCHMED |
HUTCHMED Management Team Effectiveness
The company has return on total asset (ROA) of (0.1932) % which means that it has lost $0.1932 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2472) %, meaning that it generated substantial loss on money invested by shareholders. HUTCHMED's management efficiency ratios could be used to measure how well HUTCHMED manages its routine affairs as well as how well it operates its assets and liabilities.HUTCHMED Limited has a total of 864.77 Million outstanding shares. Over half of HUTCHMED's outstanding shares are owned by outside corporations. These outside corporations are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in pink sheets such as HUTCHMED in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of HUTCHMED, and when they decide to sell, the pink sheet will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
HUTCHMED Workforce Comparison
HUTCHMED Limited is rated below average in number of employees category among its peers. The total workforce of Drug Manufacturers—Specialty & Generic industry is currently estimated at about 52,327. HUTCHMED holds roughly 2,110 in number of employees claiming about 4% of equities under Drug Manufacturers—Specialty & Generic industry.
The company has Profit Margin (PM) of (0.64) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.95) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.95. HUTCHMED Limited Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. HUTCHMED Limited Price Series Summation is a cross summation of HUTCHMED price series and its benchmark/peer.
HUTCHMED Notable Stakeholders
A HUTCHMED stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as HUTCHMED often face trade-offs trying to please all of them. HUTCHMED's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting HUTCHMED's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Selina Zhang | VP HR | Profile | |
| Kin MBA | Sr Devel | Profile | |
| Karen Atkin | Ex COO | Profile | |
| CA BEc | CFO Director | Profile | |
| CS CGP | Company Director | Profile | |
| Charles Nixon | Group Counsel | Profile | |
| Qingmei Wang | Sr Alliances | Profile | |
| Hong Chen | VP China | Profile | |
| ACGI BSc | Ex Chairman | Profile | |
| Weiguo BSc | Chief CEO | Profile |
About HUTCHMED Management Performance
The success or failure of an entity such as HUTCHMED Limited often depends on how effective the management is. HUTCHMED management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of HUTCHMED management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the HUTCHMED management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
HUTCHMED Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. The company was incorporated in 2000 and is headquartered in Central, Hong Kong. Hutchison China operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 2110 people.
HUTCHMED Workforce Analysis
Traditionally, organizations such as HUTCHMED use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare HUTCHMED within its industry.HUTCHMED Manpower Efficiency
Return on HUTCHMED Manpower
| Revenue Per Employee | 168.8K | |
| Revenue Per Executive | 35.6M | |
| Net Loss Per Employee | 92.3K | |
| Net Loss Per Executive | 19.5M |
Complementary Tools for HUTCHMED Pink Sheet analysis
When running HUTCHMED's price analysis, check to measure HUTCHMED's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HUTCHMED is operating at the current time. Most of HUTCHMED's value examination focuses on studying past and present price action to predict the probability of HUTCHMED's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HUTCHMED's price. Additionally, you may evaluate how the addition of HUTCHMED to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |